Lungs News and Research

RSS

Newer anticoagulant medication may increase risk of GI bleeding in older patients

In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.

30 May 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.

30 May 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells).

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

Airway granulocytes potential CF biomarker for fungal lung disease

Researchers have found that accumulation in the airways of CXCR4+ granulocytes is associated with chronic colonisation by the fungus Aspergillus fumigatus.

29 May 2015

Challenge remains for early COPD detection in primary care

Exhaled carbon monoxide testing in primary care has no effect on patient acceptance of screening for chronic obstructive pulmonary disease, research shows.

29 May 2015

‘Real-world’ sunitinib findings support trial results

Results of postmarketing follow-up in Japanese patients confirm the efficacy and safety profile of sunitinib in advanced renal cell carcinoma.

29 May 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

New research shows wide variation in organ donation rates across the country

More than 123,000 Americans are currently waiting for lifesaving organ transplants, but 21 patients die each day because there aren't enough organs to go around. New research shows wide variation in the number of eligible organ donors whose loved ones consent to organ donation across the country.

29 May 2015

MedUni Vienna expert suggests pricing strategy to reduce smoking

30% of the estimated 2.3 million smokers in Austria are considered to be heavily tobacco-dependent and, according to experts at MedUni Vienna, require professional treatment. This would mean around 690,000 people. According to Michael Kunze, an expert on smoking at the Center for Public Health at MedUni Vienna, an effective strategy would be to increase the price of tobacco products: "If the price of cigarettes were to rise just one percent above the inflation rate, that would bring about a 0.5% reduction in consumption worldwide."

29 May 2015

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.

29 May 2015

Study: New cases of cancer rising globally, but death rates falling in many countries

New cases of virtually all types of cancer are rising in countries globally - regardless of income - but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries.

29 May 2015

Therapy for genetically-caused emphysema slows progression of lung disease

A landmark clinical study in the Lancet provides convincing evidence that a frequently overlooked therapy for genetically-caused emphysema is effective and slows the progression of lung disease.

29 May 2015

Charged particles more common beside busy roads, reveals QUT study

Despite community concerns about living under high-voltage power lines, a world-first QUT study reveals that there are far more charged particles beside busy roads.

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015

EKF subsidiary, Selah Genomics’ newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141...

From EKF Diagnostics 28 May 2015

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

28 May 2015

Lungs News and Research

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Airway granulocytes potential CF biomarker for fungal lung disease

Challenge remains for early COPD detection in primary care

‘Real-world’ sunitinib findings support trial results

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

New research shows wide variation in organ donation rates across the country

MedUni Vienna expert suggests pricing strategy to reduce smoking

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Study: New cases of cancer rising globally, but death rates falling in many countries

Therapy for genetically-caused emphysema slows progression of lung disease

Charged particles more common beside busy roads, reveals QUT study

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

UM researcher receives grant to examine effects of CBT on racial/ethnic minority smokers

FEV1/FVC lower limit of normal aids surgery risk stratification in COPD

GOLD 2007 and 2011 fail to accurately predict mortality risk

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News